




RealRate

# MEDICINAL PRODUCTS 2020

## Celldex Therapeutics Inc. Rank 25 of 52





RealRate

# MEDICINAL PRODUCTS 2020

## Celldex Therapeutics Inc. Rank 25 of 52



The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable General and Administrative Expense, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 38%, being 43% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	66,698
Assets, Non-Current	3,514
General and Administrative Expense	15,426
Goodwill	48,690
Liabilities, Current	11,643
Liabilities, Non-Current	17,264
Other Assets	0
Other Compr. Net Income	36
Other Expenses	506
Other Liabilities	0
Other Net Income	0
Other Revenues	7,726
Property, Plant and Equipment, Net	4,031
Research and Development	42,672

Output Variable	Value in 1000 USD
Liabilities	28,907
Assets	122,933
Expenses	58,604
Revenues	7,726
Stockholders Equity	94,026
Net Income	-50,878
Comprehensive Net Income	-50,860
Economic Capital Ratio	38%